SLU-PP-332 vs Tirzepatide
A side-by-side research comparison of SLU-PP-332 and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | SLU-PP-332 | Tirzepatide |
|---|---|---|
| Full name | SLU-PP-332 (ERR Agonist) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | FDA Approved |
| Mechanism | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | ~426 Da (small molecule, not a peptide) | 4,814 Da |
| Half-life | Not well characterized in humans | 5 days (120 hours) |
| Bioavailability | Studied via injection in animals; oral activity under investigation | High (SubQ ~80%) |
| Typical dose | No established human dose | 2.5 mg → titrate up to 15 mg |
| Frequency | Unknown | Once weekly |
| Route | Injection (preclinical) | Subcutaneous injection |
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.